SPARCing chemotherapy success


Resistance to chemotherapy causes cancer treatment to be unsuccessful and is responsible for high mortality rates as a result. A number of genetic alterations are involved in chemotherapy resistance. In a study appearing online on May 12 in advance of the print publication of the June issue of the Journal of Clinical Investigation, Isabella Tai and colleagues from the University of British Columbia identify a new protein involved in tumor therapy resistance.

The authors use microarray analysis to identify genes that were involved in the resistance of cancer to chemotherapy. They identified a protein called SPARC, which was poorly expressed in human colon cells that were noncompliant to radiation and chemotherapy. Restoration of treatment sensitivity was achieved by re-expressing SPARC in these resistant cells. Treating mice with SPARC increased their sensitivity to chemotherapy and caused reduction of tumors. SPARC-based therapy could thus be useful for enhancing cancer treatment.


Contact: Stacie Bloom
Journal of Clinical Investigation

Page: 1

Related biology news :

1. Nanoparticles carry chemotherapy drug deeper into solid tumors
2. A faster way to recover from chemotherapy and marrow transplant
3. PET accurately identifies esophageal cancer patients positive responses to chemotherapy
4. Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
5. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
6. Gene analysis might explain ethnic differences in sensitivity to chemotherapy in lung cancer
7. Enhancing chemotherapys efficacy: New agent has synergistic effect with standard drugs
8. Massive gene screening points way to more effective chemotherapy
9. Researchers find the mechanism by which cells resist chemotherapy
10. Protein identified that regulates effectiveness of Taxol chemotherapy in breast cancer
11. A chemotherapy drug packs a one-two punch

Post Your Comments:

(Date:5/26/2020)... ... May 26, 2020 , ... ... today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing cancer ... and TCR-based therapeutics, has implemented Genedata Biologics ® within their R&D ...
(Date:5/21/2020)... ALPHARETTA, Ga. (PRWEB) , ... ... ... provider of Human Capital IntegritySM technology-based services specializing in background and medical ... with their COVID-19 return-to-work planning and keeping their workforce safe. The new ...
(Date:5/21/2020)... N.J. (PRWEB) , ... May 20, 2020 , ... ... development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ... Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris Virtual ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... ... March 30, 2020 , ... Kinetic Vet, an ... an EPA-approved spray-on antimicrobial solution. As a first-of-its-kind technology within the animal health ... activity against microorganisms for up to 90 days. , In addition to reducing ...
(Date:4/1/2020)... , ... March 31, 2020 ... ... Systems, B.V. (MBS) has developed a method using its revolutionary NEXTGENPCR endpoint ... minutes. Combined with smaller reaction volumes, increased samples per run, and standard, ...
(Date:4/1/2020)... ... March 31, 2020 , ... Bedoukian Research, Inc. ... a Joint Development Agreement that builds on each company’s expertise in developing efficient ... in the supply of high-quality insect pheromones as well as flavors and fragrances. ...
(Date:3/27/2020)... ... March 26, 2020 , ... iFirst Medical Technologies, Inc., a ... COVID-19 nasal swab test. , "COVID-19 poses a grave danger to public health here ... at iFirst are compelled to act. Broad-based testing and on-the-spot results promise to slow ...
Breaking Biology Technology:
Cached News: